Phase 1b dose-finding study of avelumab (anti-PD-L1) + axitinib in treatment-naïve patients with advanced renal cell carcinoma.
Authors
Larkin, JRini, B
Nathan, P
Thistlethwaite, Fiona C
Gordon, M
Martgnoni, M
Magazzu, D
Chiruzzi, C
Di Pietro, A
Choueiri, T
Affiliation
Department of Medical Oncology, Royal Marsden Hospital, LondonIssue Date
2016-10-01
Metadata
Show full item recordCitation
Phase 1b dose-finding study of avelumab (anti-PD-L1) + axitinib in treatment-naïve patients with advanced renal cell carcinoma. 2016, 27(suppl_6):775PD Annals of OncologyJournal
Annals of OncologyDOI
10.1093/annonc/mdw373.03Additional Links
https://academic.oup.com/annonc/article/2799512/PhaseType
Meetings and ProceedingsLanguage
enISSN
0923-75341569-8041
ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdw373.03